TAmiRNA is proud to contribute to a newly published peer-reviewed study demonstrating the independent validation of circulating microRNAs (miRNAs) as biomarkers in adolescents with long-standing type 1 diabetes (T1D).

The study, published in PLOS ONE (2026), strengthens growing evidence that circulating microRNAs serve as minimally invasive biomarkers with potential applications in disease monitoring and precision medicine.

Study Overview: microRNA Biomarkers in Adolescent Type 1 Diabetes

Reliable biomarkers are essential for improving disease monitoring and long-term management of type 1 diabetes. MicroRNAs — small, non-coding RNA molecules regulating gene expression — are detectable in blood and have emerged as promising non-invasive diagnostic and prognostic tools.

This case-control study investigated previously reported circulating miRNAs in:

  • 24 adolescents with type 1 diabetes (disease duration 8–16.5 years)
  • 24 age- and sex-matched healthy controls

Using quantitative PCR (qPCR) microRNA analysis, 23 candidate miRNAs were evaluated to independently confirm earlier findings.

Key Findings

The study identified:

  • Twelve significantly dysregulated circulating miRNAs in adolescents with long-term T1D compared to healthy controls
  • Notable biomarkers including miR-223-3p and miR-135a-5p, previously associated with inflammatory and cardiovascular pathways
  • Correlations between specific miRNAs and clinical parameters such as HbA1c levels and disease duration

These findings provide robust independent validation of circulating microRNA signatures in type 1 diabetes and support their potential role in biomarker development.

Clinical and Translational Impact

The validation of circulating miRNAs in an independent cohort is a critical step toward:

  • Developing precision diagnostic tools in type 1 diabetes
  • Improving long-term disease monitoring
  • Complementing traditional clinical markers with molecular biomarkers
  • Advancing personalized medicine approaches in metabolic disease

While further large-scale studies are required, this work reinforces the scientific foundation for miRNA-based biomarker strategies in chronic autoimmune disorders.

TAmiRNA’s Role in Advancing microRNA Biomarker Research

TAmiRNA contributed its expertise in:

  • High-precision microRNA quantification
  • Biomarker validation workflows
  • Translational data analysis
  • Standardized qPCR methodologies

We are happy to have contributed to the research published by our collaborators at the Göteborgs universitet, Linköpings universitet and the Ludwig Boltzmann Institute for Traumatology, The Research Center in Cooperation with AUVA.